Introduction
Post-traumatic seizures are one of the important but poorly understood sequelae of head injury (HI), or, more specifically, traumatic brain injury (TBI).1 They can occur either early (within 1 week of the injury) or late (from 1 week to years after the trauma).1 The particular significance of early post-traumatic seizures (EPTS) lies in the fact that a seizure attack within the acute stage of HI may result in brain hypoxia, triggering cerebral hyperaemia, increased neuronal metabolic demand, increased release of proinflammatory and excitotoxic neurotransmitters, and, finally raised intracranial pressure (ICP) and secondary brain damage; all together leading to higher morbidity and mortality.2 3
Because post-traumatic seizures have such negative impact on outcome, patients with TBI are routinely given preventive antiseizure medications by some clinicians.4 However, there is only conflicting evidence to show that prophylactic antiseizure medications have the ability to reduce the incidence of EPTS.1 5 What is more, there are documented potential complications of the use of these drugs in the brain-injured patients. For instance, there are some animal data documenting that early treatment with benzodiazepines impairs both neuroplasticity and fundamental brain repair processes.6 Phenytoin and carbamazepine, each a common antiseizure medication in clinical use, have also been shown to impact negatively on cognitive performance in patients who received these agents for seizure prophylaxis after brain injury.7 In high-resource settings, levetiracetam is now largely preferred to phenytoin for post-traumatic seizure prophylaxis, partly because of better side effect profile.
In our own part of the world, that is, Nigeria, a low/middle-income country in sub-Saharan Africa, there is no known national clinical protocol on antiseizure-prophylaxis in patients with TBI and this modality, to our knowledge, is not practised by the majority of our neurosurgical centres. In our practice, specifically, antiseizure-prophylaxis in patients with TBI is not practised, rather antiseizure medications are commenced therapeutically only after onset of seizure in each case.
The cost of procuring these medications is another consideration in our privately funded healthcare system. Here, the patients, most of whom live below the poverty line, pay out-of-pockets for all the expenses of their in-hospital care. In addition, levetiracetam is more expensive (>20 times) and less widely available than phenytoin. Therefore, the latter is still the first drug of choice widely used in the management of seizures, including post-traumatic ones, in our own practice.
Whereas it might be prudent to avoid long-term phenytoin prophylaxis in patients with TBI based on of the efficacy data and risks associated with its use; but since the risks associated with short-term therapy are often dose related (and hence avoidable) and because about half to two-thirds of EPTS occur in the first 24 hours, short-term phenytoin therapy might be a pragmatic choice after all.4 8
This study aims to evaluate the effectiveness of a short-course (48-hour dose) prophylactic administration of phenytoin, a relatively cheap and widely available antiseizure medication in our setting, in prevention of EPTS in a cohort of patients with TBI.